Science

ARCI develops magnetocaloric material for cancer treatment

V Rishi Kuma Hyderabad | Updated on June 07, 2020 Published on June 07, 2020

Scientists at the International Advanced Research Centre for Powder Metallurgy and New Materials (ARCI), an autonomous R&D centre of the Department of Science and Technology, have developed a rare-earth-based magnetocaloric material that can be effectively used for cancer treatment.

The magnetocaloric materials (certain materials in which application and removal of a magnetic field causes the materials to become warmer or cooler) developed by ARCI are being tested at Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST). A paper on the research work has been published in the Journal of Alloys and Compounds.

Advancements in magnetic materials led to the development of magnetic hyperthermia to try to address the issues of side effects of cancer treatment like chemotherapy. In magnetic hyperthermia, magnetic nanoparticles are subjected to alternating magnetic fields of few Gauss, which produce heat due to magnetic relaxation losses. Usually, the temperature required to kill the tumor cells is between 40 and 45°C. However, the drawback in magnetic hyperthermia is the lack of control of temperature, which may damage the healthy cells in the body and also have side effects like increased blood pressure etc.

These problems can be avoided by using magnetocaloric materials, as it can provide controlled heating. The advantage of magnetocaloric materials which heat up or cool down with the application and removal of the magnetic field, respectively is that as soon as the magnetic field is removed, cooling effect is generated, unlike in magnetic nanoparticles where overheating persists, even after removal of the magnetic field.

The team at ARCI chose rare-earth-based alloy for studies as some of the rare earth materials are human body compatible. They optimized the alloy composition so that the Curie temperature came close to the therapeutic range (42-460 C) required for destroying cancer cells.

With the application of the magnetic field on dry powders, the temperature of the rare-earth nanoparticles rose to 590 C.

This method, when used in conjunction with radiation therapy, according to a statement would reduce the side effects, damage caused to the human body and also reduce the treatment time of cancer tumours.

Published on June 07, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
WHO resumes malaria drug trial on Covid-19 patients